BFM
TPTX

Boothbay Fund Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Boothbay Fund Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,089
Closed -$272K – 2400
2021
Q3 		$272K Buy
4,089
+114
+3% +$8.12K 0.01% 1382
2021
Q2 		$310K Buy
+3,975
New +$294K 0.01% 1256

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boothbay Fund Management's TPTX Position: Q4 2021 in Review

Boothbay Fund Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 4,089 shares — an estimated $272K sold.

Boothbay Fund Management first reported a position in TPTX in Q2 2021 and held it in 2 quarters. The position peaked at $310K in Q2 2021. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

  • Boothbay Fund Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 4,089 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $272K.
  • Boothbay Fund Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Boothbay Fund Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $310K in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.